Atlas Trials

Macular Degeneration

278 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Macular Degeneration

RecordFirmDate
Genetic Factors in Age-Related Macular Degeneration (NCT00058695)National Eye Institute (NEI)2003-04-04
A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration (NCT00056836)Genentech, Inc.2003-03-01
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD (NCT00058994)Alcon Research2003-03-01
Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate (NCT00349739)University of Iowa2003-01-01
Laser and Medical Treatment of Diabetic Macular Edema (NCT00050479)National Eye Institute (NEI)2002-12-01
Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD) (NCT00095433)Genentech, Inc.2002-09-01
Efficacy of Electrical Micro-current Retinal Stimulation for Treatment of Dry Age-related Macular Degeneration (NCT01600300)Acuity Medical International, Inc.2002-08-01
Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy (NCT00043680)National Eye Institute (NEI)2002-08-01
Multi-Ethnic Study of Atherosclerosis (MESA) - Ancillary Eye Study (NCT00041444)University of Wisconsin, Madison2002-06-01
Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD (NCT00041483)Alcon Research2002-06-01
Visudyne® in Occult (VIO) (NCT00121407)QLT Inc.2002-03-01
A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration (NCT00032396)Control Delivery Systems2001-11-01
Phase II/III Study of Anti-VEGF in Neovascular AMD (NCT00021736)Eyetech Pharmaceuticals2001-07-01
Identification and Treatment of Feeder Vessels in Macular Degeneration (NCT00018070)National Eye Institute (NEI)2001-06-28
Preventing Depression in Patients With Macular Degeneration (NCT00042211)Thomas Jefferson University2001-02-01
Fluocinolone Implant to Treat Macular Degeneration (NCT00008515)National Eye Institute (NEI)2001-01-01
Lutein for Age-Related Macular Degeneration (NCT00006202)National Eye Institute (NEI)2000-09-01
Rheopheresis Blood Filtration Study for the Treatment of Dry Age-Related Macular Degeneration (AMD) (NCT00078221)OccuLogix1999-08-01
Complications of Age-Related Macular Degeneration Prevention Trial (NCT00000167)National Eye Institute (NEI)1999-05-01
Submacular Surgery Trials (SST) (NCT00000150)National Eye Institute (NEI)1999-01-01
Screening for Studies on Retinovascular Diseases (NCT00001733)National Eye Institute (NEI)1998-03-06
Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular Degeneration (NCT00001615)National Eye Institute (NEI)1997-07-01
Long Term Follow-Up of Diabetic Retinopathy (NCT00001395)National Eye Institute (NEI)1994-03-01
Randomized Trials of Vitamin Supplements and Eye Disease (NCT00000161)National Eye Institute (NEI)1993-08-01
Diabetic Retinopathy and Visual Function Study (NCT00001346)National Eye Institute (NEI)1992-11-01
Age-Related Eye Disease Study (AREDS) (NCT00000145)National Eye Institute (NEI)1990-09-01
Randomized Trial of Beta-Carotene and Macular Degeneration (NCT00000152)National Eye Institute (NEI)1982-04-01
Macular Photocoagulation Study (MPS) (NCT00000158)National Eye Institute (NEI)1979-02-01
Branch Vein Occlusion Study (NCT00000162)National Eye Institute (NEI)1977-07-01
Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD) (NCT00109499)GenVec
A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Branch Retinal Vein Occlusion (NCT00308477)Sanwa Kagaku Kenkyusho Co., Ltd.
Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab (NCT00804921)University of Sao Paulo
← Previous

Track Macular Degeneration automatically

Every clearance here is in the API, with alerts when new ones post.